MindMed Q2 net loss widens to $42.7 mln, R&D costs rise

Definium Therapeutics

31/07/2025 21:09

Overview

MindMed reports Q2 net loss of $42.7 mln, up from $5.9 mln last year

R&D expenses rise to $29.8 mln in Q2, driven by MM120 ODT program

Company appoints Brandi L. Roberts as CFO to strengthen leadership team

Outlook

Company's cash expected to fund operations into 2027

Result Drivers

R&D EXPENSES - Increased R&D expenses driven by MM120 ODT program advancements

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.5
Q2 Net Income
-$42.74 mln
Q2 Basic EPS
-$0.5
Q2 Income from Operations
-$40.90 mln
Q2 Operating Expenses
$40.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Mind Medicine (MindMed) Inc is $20.00, about 54.9% above its July 30 closing price of $9.03

Press Release: ID:nBw2zY4bva

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)